首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys
【24h】

Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys

机译:长期使用mGlu5受体拮抗剂治疗对帕金森病猴脑中5-羟色胺标志物的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In Parkinson's disease (PD) and L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs), overactivity of brain glutamate neurotransmission is documented and antiglutamatergic drugs decrease LID. Serotonin (5-HT) receptors and transporter (SERT) are also implicated in LID and we hypothesize that antiglutamatergic drugs can also regulate brain serotoninergic activity. Our aim was to investigate the long-term effect of the prototypal metabotropic glutamate 5 (mGlu5) receptor antagonist 2-methyl-6-(phenylethynyl) pyridine (MPEP) with L-DOPA on basal ganglia SERT, 5-HT1A and 5-HT2A receptor levels in monkeys lesionedwith 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). MPTP monkeys were treated for one month with L-DOPA and developed LID while those treated with L-DOPA andMPEP (10 mg/kg) developed significantly less LID. Normal controls and saline-treated MPTP monkeys were included for biochemical analysis. The MPTP lesion and experimental treatments left unchanged striatal 5-HT concentrations. MPTP lesion induced an increase of striatal 5-HIAA concentrations similar in all MPTP monkeys as compared to controls. [H-3]-8-OH-DPAT and [H-3]-citalopram specific binding levels to 5-HT1A receptors and SERT respectively remained unchanged in the striatum and globus pallidus of all MPTP monkeys compared to controls and no difference was observed between groups of MPTP monkeys. [3H]-ketanserin specific binding to striatal and pallidal 5-HT2A receptors was increased in L-DOPA-treated MPTP monkeys as compared to controls, saline and L-DOPA + MPEP MPTP monkeys and no difference between the latter groups was observed; dyskinesia scores correlated positively with this binding. In conclusion, reduction of development of LID with MPEP was associated with lower striatal and pallidal 5-HT2A receptors showing that glutamate activity also affects serotoninergic markers. (C) 2014 Elsevier Inc. All rights reserved.
机译:在帕金森氏病(PD)和L-3,4-二羟基苯丙氨酸(L-DOPA)诱导的运动障碍(LIDs)中,有文献记载脑谷氨酸神经传递过度活跃,抗谷氨酸能药物降低LID。 5-羟色胺(5-HT)受体和转运蛋白(SERT)也与LID有关,我们推测抗谷氨酸能药物也可以调节大脑的5-羟色胺能。我们的目的是研究原型代谢型谷氨酸5(mGlu5)受体拮抗剂2-甲基-6-(苯基乙炔基)吡啶(MPEP)与L-DOPA对基底神经节SERT,5-HT1A和5-HT2A的长期影响1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)损伤的猴子体内的受体水平用L-DOPA治疗MPTP猴子一个月并发展出LID,而用L-DOPA和MPEP(10 mg / kg)治疗的那些猴子的LID明显减少。包括正常对照和生理盐水处理的MPTP猴子,用于生化分析。 MPTP病变和实验治疗使纹状体5-HT浓度保持不变。与对照组相比,MPTP损伤引起所有MPTP猴子的纹状体5-HIAA浓度增加。与对照组相比,所有MPTP猴的纹状体和苍白球的[H-3] -8-OH-DPAT和[H-3]-西酞普兰对5-HT1A受体和SERT的特异性结合水平分别保持不变。在MPTP猴子群之间。与对照组,生理盐水和L-DOPA + MPEP MPTP猴子相比,在L-DOPA处理的MPTP猴子中,[3H]-酮色林与纹状体和苍白的5-HT2A受体的特异性结合增加,并且在后两组之间没有观察到差异。运动障碍评分与此绑定正相关。总之,用MPEP减少LID的发展与较低的纹状体和苍白的5-HT2A受体有关,表明谷氨酸活性也影响5-羟色胺能标记。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号